#1 Clinical Trials Search in Europe

Nemtabrutinib

Nemtabrutinib, also known as MK-1026 or ARQ 531, is an investigational drug being studied in clinical trials for the treatment of various hematologic malignancies. These trials aim to evaluate the safety, efficacy, and pharmacokinetics of nemtabrutinib in patients with conditions such as chronic lymphocytic leukemia, lymphomas, and other blood cancers. The research focuses on understanding how the drug works in the body and its potential benefits for patients who have not responded well to other treatments.

Table of Contents

What is Nemtabrutinib?

Nemtabrutinib, also known as MK-1026 or ARQ 531, is a new medication being developed to treat various types of blood cancers[1]. It belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors. BTK is a protein that plays a crucial role in the growth and survival of certain types of cancer cells, particularly in blood cancers[2].

How Does Nemtabrutinib Work?

Nemtabrutinib works by blocking the action of the BTK protein in cancer cells. By doing so, it helps to stop or slow down the growth and spread of cancer cells in the body. What makes nemtabrutinib unique is that it’s designed to be effective even in cases where other BTK inhibitors have stopped working due to mutations in the cancer cells[3].

What Conditions Does Nemtabrutinib Treat?

Nemtabrutinib is being studied for the treatment of several types of blood cancers, including:

  • Chronic Lymphocytic Leukemia (CLL): A slow-growing cancer of the blood and bone marrow that affects white blood cells
  • Small Lymphocytic Lymphoma (SLL): A type of cancer very similar to CLL but primarily affecting the lymph nodes
  • Waldenström’s Macroglobulinemia: A rare type of blood cancer that starts in the white blood cells
  • Mantle Cell Lymphoma: A rare, aggressive type of B-cell non-Hodgkin lymphoma
  • Follicular Lymphoma: A type of non-Hodgkin lymphoma that usually grows slowly
  • Marginal Zone Lymphoma: A slow-growing type of B-cell non-Hodgkin lymphoma
  • Richter’s Transformation: A rare condition where CLL or SLL transforms into a more aggressive lymphoma

These conditions are being studied in various clinical trials to determine the effectiveness of nemtabrutinib in treating them[4][5].

Nemtabrutinib in Clinical Trials

Nemtabrutinib is currently being evaluated in several clinical trials to assess its safety and effectiveness. These trials are being conducted in different phases:

  • Phase 1 trials: These early studies focus on determining the safe dose of nemtabrutinib and understanding how it works in the body[6].
  • Phase 2 trials: These trials are examining how well nemtabrutinib works in treating specific blood cancers[5].
  • Phase 3 trials: These larger trials are comparing nemtabrutinib to existing treatments to see if it’s more effective or has fewer side effects[7].

One notable Phase 3 trial is comparing nemtabrutinib to other BTK inhibitors (ibrutinib or acalabrutinib) in patients with untreated CLL or SLL. This study aims to determine if nemtabrutinib is as effective or potentially better than these existing treatments[7].

How is Nemtabrutinib Administered?

Nemtabrutinib is taken orally in the form of tablets. In most clinical trials, it’s being administered once daily. The exact dosage can vary depending on the specific study and condition being treated. Some trials are testing doses ranging from 45 mg to 65 mg per day[1][4].

Potential Side Effects

As with any medication, nemtabrutinib may cause side effects. While the full safety profile is still being established through clinical trials, some potential side effects that are being monitored include:

  • Hematological effects (changes in blood cell counts)
  • Gastrointestinal issues (nausea, vomiting, diarrhea)
  • Fatigue
  • Rash
  • Changes in liver function

It’s important to note that not everyone experiences side effects, and the severity can vary from person to person. The clinical trials are closely monitoring these effects to ensure patient safety[5].

Drug Interactions

Researchers are also studying how nemtabrutinib interacts with other medications. Specific studies are looking at its interaction with:

  • Efavirenz: A medication used to treat HIV
  • Itraconazole: An antifungal medication
  • Digoxin: A heart medication

These studies help determine if nemtabrutinib affects the levels of these drugs in the body or vice versa, which is crucial information for safe use in patients who may be taking multiple medications[8][9][10].

Future Prospects

Nemtabrutinib shows promise in treating various blood cancers, especially in cases where other treatments have stopped working. If the ongoing clinical trials continue to show positive results, it could become an important new option for patients with these challenging conditions. However, it’s important to remember that the drug is still in the testing phase and not yet approved for general use. Patients interested in nemtabrutinib should discuss with their healthcare providers about the possibility of participating in clinical trials[7].

Aspect Details
Drug Name Nemtabrutinib (MK-1026, ARQ 531)
Type of Drug Investigational treatment for hematologic malignancies
Administration Oral tablets, typically once daily
Target Conditions Chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström’s macroglobulinemia, various lymphomas
Clinical Trial Phases Phase 1 and Phase 2 studies
Primary Objectives Safety, tolerability, pharmacokinetics, efficacy
Key Measurements Dose-limiting toxicities, adverse events, objective response rate, duration of response
Special Populations Patients with relapsed or refractory hematologic malignancies
Ongoing Research Food effect studies, drug interactions, dosage optimization

FAQ

  • What is nemtabrutinib? Nemtabrutinib is an investigational drug being studied for the treatment of various blood cancers, including chronic lymphocytic leukemia and lymphomas. It is also known by the names MK-1026 and ARQ 531.
  • What types of cancer is nemtabrutinib being studied for? Nemtabrutinib is being studied for several hematologic malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström's macroglobulinemia, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
  • How is nemtabrutinib administered? Nemtabrutinib is administered orally, usually once daily. It comes in tablet form and is typically taken under fasting conditions, either 1 hour before or 2 hours after a meal.
  • What are the main goals of the clinical trials studying nemtabrutinib? The main goals of the clinical trials are to evaluate the safety, tolerability, and effectiveness of nemtabrutinib. Researchers are also studying how the drug is processed in the body (pharmacokinetics) and its effects on the body (pharmacodynamics).
  • Are there any known side effects of nemtabrutinib? As with all investigational drugs, the full range of potential side effects is still being studied. The clinical trials are carefully monitoring for any adverse events. Common side effects observed in cancer treatments may include fatigue, nausea, and changes in blood cell counts, but specific side effects for nemtabrutinib will be determined through the ongoing research.

Ongoing Clinical Trials on Nemtabrutinib

  • Study on the Effectiveness and Safety of Nemtabrutinib for Patients with Blood Cancers, Including CLL, SLL, MCL, MZL, FL, and Waldenström’s Macroglobulinemia

    Recruiting

    1 1 1
    Investigated drugs:
    Czechia Denmark France Germany Hungary Ireland +4

  • Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Estonia Germany Ireland Italy Poland +3

Glossary

  • Hematologic Malignancies: Cancers that affect blood, bone marrow, and lymph nodes. These include leukemias, lymphomas, and myelomas.
  • Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects white blood cells called lymphocytes, typically developing slowly over time.
  • Small Lymphocytic Lymphoma (SLL): A type of non-Hodgkin lymphoma affecting lymphocytes, very similar to CLL but primarily found in lymph nodes.
  • Waldenström's Macroglobulinemia: A rare type of blood cancer that begins in the white blood cells and overproduces certain proteins.
  • Mantle Cell Lymphoma: An aggressive form of non-Hodgkin lymphoma that affects lymphocytes in the 'mantle zone' of lymph nodes.
  • Follicular Lymphoma: A type of non-Hodgkin lymphoma that typically grows slowly and affects B-lymphocytes.
  • Marginal Zone Lymphoma: A slow-growing type of non-Hodgkin lymphoma that develops from B-lymphocytes in the marginal zone of lymphoid tissue.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and biochemical effects.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without the cancer growing or spreading.

References

  1. https://clinicaltrials.gov/study/NCT05673460
  2. https://clinicaltrials.gov/study/NCT06586671
  3. https://clinicaltrials.gov/study/NCT06442436
  4. https://clinicaltrials.gov/study/NCT05347225
  5. https://clinicaltrials.gov/study/NCT04728893
  6. https://clinicaltrials.gov/study/NCT03162536
  7. https://clinicaltrials.gov/study/NCT06136559
  8. https://clinicaltrials.gov/study/NCT06698016
  9. https://clinicaltrials.gov/study/NCT06688045
  10. https://clinicaltrials.gov/study/NCT06625827